Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper -- February 2019.

The article looks at a position paper that includes data on the effects of the 10- and 13-valent pneumococcal conjugate vaccines published up to June 2017. The position paper addresses the dosing schedule, product choice, and the value of catch-up vaccination in children under five years of age. Around 75 percent of cases of invasive pneumococcal disease occur in children aged over two years. Some serotypes are more likely than others to be resistant to antimicrobials.